What exactly counts as treatment-resistant depression?

The standard clinical definition is major depression that hasn't responded adequately to at least two different antidepressant medications, each tried at a therapeutic dose for 6-8 weeks. Some definitions require the two failed medications be from different drug classes. 'Not responding' usually means failing to achieve remission, not just failing to improve at all — partial response is very different from no response, and changes the treatment approach.

How common is treatment-resistant depression?

Estimates range from 30% to 50% of people with major depressive disorder will meet criteria for treatment resistance at some point. The large STAR*D trial found that only about 37% of patients achieved remission on the first medication tried. After two sequential medication trials, cumulative remission was roughly 50%. So having two medications fail is the experience of about half the people who start treatment — it's the rule, not the exception.

Is ketamine really FDA-approved for depression?

Esketamine (the nasal spray form, brand name Spravato) is FDA-approved for treatment-resistant depression and for depressive symptoms in adults with major depression who have acute suicidal ideation. Intravenous ketamine itself is not FDA-approved for depression, but is widely used off-label at ketamine clinics under physician supervision. Both are administered in-office with monitoring because of dissociative effects.

Does TMS really work or is it expensive placebo?

TMS has genuine evidence behind it. Multiple randomized sham-controlled trials show efficacy superior to placebo, and real-world response rates run around 50-60% with remission rates around 30-40% in treatment-resistant populations. It's FDA-approved for TRD after at least one failed antidepressant. The main catch is time — typical protocols require 4-6 weeks of daily sessions.

Should I keep trying medications or skip to advanced treatments?

There's no universal answer, but if you've had two adequate trials fail, it's worth discussing augmentation strategies (lithium, T3, atypical antipsychotics) and more advanced interventions (TMS, ketamine) in parallel with considering further medication switches — not as a last resort after five more years of trying pills. Modern treatment algorithms increasingly move to TMS or ketamine after 2-3 failed medications rather than waiting indefinitely.

Treatment-Resistant Depression: What It Means and What Actually Works

You try the first antidepressant. Six weeks in, nothing much has changed — maybe the sleep is a little better, but the weight on your chest is exactly where it was. Your prescriber switches you to a second one. Another six weeks. Still nothing. At this point, a phrase starts showing up in your chart that feels like a verdict: treatment-resistant depression.

It sounds worse than it is. Treatment-resistant depression (TRD) isn't a dead end or a different kind of illness. It's a clinical label that means the first couple of tools haven't worked, and it's time to use different ones. Somewhere between 30% and 50% of people with major depressive disorder end up in this category — so if that's you, it's not rare, and it's not the end of the road.

What follows is an honest map of what TRD actually means, why some medications fail, and what the evidence says about the next steps. Bring this to your psychiatrist. Ask better questions. Don't let six frustrating weeks with one pill become the story of your life.

What "Treatment-Resistant" Actually Means

There isn't one universally agreed-upon definition, which is part of the problem. The working clinical definition most psychiatrists use is this: major depression that hasn't responded to at least two adequate trials of different antidepressants. An "adequate trial" usually means 6-8 weeks at a therapeutic dose.

That definition has a few quiet assumptions baked into it. First, it assumes you took the medication as prescribed — missed doses don't count as a failed trial. Second, it assumes the dose was actually therapeutic, not the starting dose your prescriber forgot to increase. Third, it assumes the diagnosis itself is right.

The big STAR*D trial, one of the largest real-world studies of depression treatment ever run, followed nearly 3,000 patients through up to four sequential treatment steps. The results were humbling: after the first medication (citalopram), only about 37% achieved remission. After two treatment steps, the cumulative figure was roughly 50%. By the fourth step, cumulative remission reached about 67% — but each additional step had diminishing returns, and relapse rates went up the further you went. Rush et al. (2006) laid this out in detail.

Translation: roughly one in three people with depression won't achieve remission even after four serious tries. That's not a failure of effort — that's a feature of the illness, and it means the approach has to evolve, not just repeat.

Before Calling It Resistant: Things to Rule Out

Before anyone labels your depression "resistant," a good clinician checks for things that look like depression but aren't, or things that make depression worse underneath the surface.

Thyroid Problems

Hypothyroidism mimics depression with stunning accuracy — fatigue, low mood, weight changes, cognitive fog. If your TSH hasn't been checked, that's step one. Subclinical hypothyroidism (TSH at the upper end of normal) can still worsen depression, and some psychiatrists will augment with thyroid hormone even when labs look borderline.

Bipolar Disorder Missed as Depression

This is the big one. People with bipolar II disorder often get diagnosed as "treatment-resistant depression" because their hypomanic episodes are subtle or never asked about. Antidepressants alone can actually worsen bipolar depression or destabilize mood. If you've had periods of unusually high energy, racing thoughts, or reduced need for sleep — even briefly — tell your prescriber. A bipolar diagnosis changes the entire treatment approach.

Sleep Apnea

Untreated sleep apnea causes fragmented sleep, daytime fatigue, and mood symptoms that look exactly like depression. If you snore, wake unrefreshed, or have been told you stop breathing at night, a sleep study should come before calling it resistant.

Substance Use

Alcohol is the main one, and a lot of people underestimate their intake. Regular alcohol use — even a few drinks most nights — interferes with both serotonin systems and sleep architecture in ways that blunt antidepressant effect.

The Wrong Medication for the Subtype

Depression isn't one thing. Melancholic depression (with early-morning awakening, weight loss, psychomotor slowing) responds differently than atypical depression (with oversleeping, overeating, mood reactivity). Anxious depression needs different strategies than anhedonic depression. If you've been on three SSRIs in a row, that's not really three different medications — it's three variations on the same approach. Sometimes the problem is needing a different mechanism, not a different drug in the same class.

What Comes After Two Failed Medications

Once genuine treatment resistance is established, there are several evidence-based next moves. These generally fall into four buckets: switch, combine, augment, or step up to advanced treatments.

Switch to a Different Class

If two SSRIs haven't worked, moving to an SNRI (venlafaxine, duloxetine) is standard. If SNRIs also fail, atypical antidepressants like bupropion or mirtazapine use different mechanisms. Bupropion hits dopamine and norepinephrine. Mirtazapine works on histamine and certain serotonin receptors — it's sedating and tends to help sleep and appetite.

The SSRI class itself has dose-dependent effects that some prescribers don't push far enough. A meta-analysis of 40 randomized trials found that higher doses of SSRIs produce slightly better outcomes, with benefit plateauing around the equivalent of 50mg of fluoxetine. Jakubovski et al. (2016) suggests that if your dose feels low and you're not at max tolerated, that's a conversation to have before declaring the medication failed.

Augmentation

Instead of switching, you add something to what's already working partially. The best-evidenced augmenters for treatment-resistant depression include:

Lithium. Used for decades, still one of the most effective augmentation strategies. Requires blood monitoring but can convert non-responders to responders.
Atypical antipsychotics. Aripiprazole, quetiapine, and olanzapine-fluoxetine combinations have FDA approval as add-ons for TRD. Side effect profiles matter here — weight gain and metabolic effects aren't trivial.
Thyroid hormone (T3). Liothyronine added to an existing antidepressant has shown benefit even in people with normal thyroid labs. Smaller effect size than lithium, but better tolerated.
Bupropion added to an SSRI. Common combination that can help with both mood and the sexual side effects SSRIs often cause.

Ketamine and Esketamine

This is the most significant development in depression treatment in decades. Ketamine, originally an anesthetic, produces rapid antidepressant effects — sometimes within hours — through glutamate signaling rather than the monoamine systems traditional antidepressants target.

The landmark randomized trial by Zarate et al. (2006) tested a single IV ketamine infusion in patients with treatment-resistant depression. Significant improvement showed up within 110 minutes. By 24 hours, 71% of ketamine-treated subjects met response criteria and 29% were in remission. Effects lasted about a week from a single dose.

Esketamine (Spravato) is the FDA-approved intranasal form. It's administered in a clinic setting with monitoring afterward because of dissociative effects. Insurance coverage exists but is uneven, and out-of-pocket costs can be high. IV ketamine remains off-label for depression but is widely available at specialty clinics.

This is real medicine for treatment-resistant cases, not hype. That said, effects don't last forever — maintenance dosing is usually required, and long-term data are still being gathered.

TMS (Transcranial Magnetic Stimulation)

TMS uses magnetic pulses to stimulate a specific region of the prefrontal cortex. It's FDA-approved for treatment-resistant depression after one failed antidepressant trial. Typical protocols involve daily sessions over 4-6 weeks, each lasting 20-40 minutes. No anesthesia, no downtime — patients typically drive themselves home.

Response rates in real-world TMS data hover around 50-60%, with remission rates around 30-40%. It's generally well-tolerated; the main side effect is scalp discomfort during stimulation. Most major insurers cover it for TRD, though prior authorization can be onerous.

ECT (Electroconvulsive Therapy)

Despite its reputation, modern ECT is nothing like the old horror-movie version. It's done under general anesthesia with muscle relaxants, takes about 15 minutes, and patients typically don't remember the procedure. For severe, medication-resistant, or psychotic depression, ECT remains the most effective treatment available — response rates around 70-80% in some studies.

The downsides are real: short-term memory effects are common, most resolve over weeks to months, and a smaller subset experience longer-lasting gaps. For people whose depression is dangerous — suicidal, not eating, not functioning — ECT is often the right call even with its costs.

The Therapy Piece People Forget

When depression resists medication, the reflex is to keep adjusting medication. That's incomplete. Cognitive behavioral therapy (CBT), behavioral activation, and interpersonal therapy all have strong evidence bases, and combining medication with structured therapy consistently outperforms medication alone — particularly for people who've already failed single-agent treatment.

The evidence for adding CBT or behavioral activation to an antidepressant in TRD is strong enough that any treatment plan without a therapy component is incomplete. If your only intervention for six months has been escalating medications, something is missing.

Psychedelic-Assisted Therapy: Where We Actually Are

Psilocybin, MDMA, and ayahuasca-based therapies are in late-stage clinical research for treatment-resistant depression. Psilocybin, in particular, has breakthrough therapy designation from the FDA and early trial data is promising — a significant subset of patients show sustained response after just one or two supervised sessions.

As of 2026, psilocybin therapy is not FDA-approved. Oregon and Colorado have state-level psilocybin services programs, but these are not medical treatments and aren't covered by insurance. If you hear ads for "psychedelic therapy," be cautious — some clinics are offering expensive off-label ketamine-assisted psychotherapy and calling it psychedelic therapy. That's real medicine but it's not psilocybin.

What to Ask Your Psychiatrist

If you're stuck, these are the questions that move a plan forward:

Have we confirmed this is unipolar depression and not bipolar? What screening did we do?
Was my last medication trial at maximum tolerated dose for 6-8 weeks?
Have we tested thyroid function, vitamin D, B12, and iron recently?
What augmentation options fit my situation — lithium, T3, atypical antipsychotic?
Am I a candidate for TMS or esketamine? What's the process to try it?
Am I working with a therapist? If not, can you refer me to someone with CBT or behavioral activation training?

The Thing Nobody Tells You

Treatment-resistant depression is demoralizing in a particular way — you did what the doctor said, took the pill, and it didn't work, and now part of you wonders if you're just uniquely broken. That framing is wrong and it costs people years.

TRD is a sign that the system is complex, that monoamine-based medications don't hit everyone's depression, and that different mechanisms exist for good reasons. The people who eventually respond to TMS after failing four medications, or ketamine after failing seven, aren't somehow "more depressed" than the person who remitted on the first SSRI. They needed a different tool, and it took longer to find it.

Keep going. Keep pushing back against flat treatment plans. If your current psychiatrist isn't exploring advanced options, ask for a second opinion at an academic medical center or a specialty mood disorders clinic. The state of the art is moving fast, and what was resistant five years ago has meaningfully different answers today.

Practical Takeaways

Treatment-resistant depression means two adequate medication trials haven't worked — nothing more, nothing less. Roughly one-third of people with depression fit this definition. It's common, not catastrophic.
Before labeling it resistant, rule out bipolar disorder, thyroid issues, sleep apnea, and substance use. These mimic or worsen depression and often get missed in primary care.
Make sure each medication was an adequate trial. 6-8 weeks at a therapeutic dose, taken consistently. Three "failed" trials at subtherapeutic doses aren't really three trials.
Augmentation often beats switching. Lithium, T3 thyroid hormone, atypical antipsychotics, or adding bupropion can convert partial responders into full responders.
Ketamine/esketamine and TMS are real, evidence-based options for genuine TRD. Don't wait five years to try them if you've already failed multiple medications.
Therapy matters, especially when medication is only partially working. CBT and behavioral activation have strong data as adjuncts in TRD.
If your psychiatrist isn't pushing the plan forward, get a second opinion. Academic medical centers and specialty mood disorder clinics are worth the drive.